AcelRx Pharmaceuticals Inc. (ACRX) shares were rising 10.95% to trade at $0.31 in pre-market at last check. AcelRx (ACRX) stock lost -6.87% to close Tuesday’s session at $0.28. The stock volume remained 5.28 million shares, which was higher than the average daily volume of 1.0 million shares within the past 50 days. ACRX stock is surging pre-hours after the release of comparative data around dialysis.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
What information has ACRX shared?
AcelRx (ACRX) is a pharmaceutical company that develops and markets new treatments that are used under medical supervision. Sufentanil is delivered using non-invasive sublingual technology, resulting in consistent pharmacokinetic characteristics. Currently, DSUVIA (sufentanil sublingual tablet, 30 mcg), also known as DZUVEO in Europe, is approved for the management of acute pain severe enough to require an opioid analgesic in adult patients under medical supervision in certified healthcare facilities, and the company has several other products in development.
AcelRx (ACRX) announced it has published a study comparing two different dialysis circuit anticoagulants (CRRT) in pediatric renal replacement therapy patients.
- South Korea and Japan use nafamostat extensively for dialysis anticoagulation. Nafamostat is not commercially available in the United States or the EU, but regional citrate anticoagulation (RCA) is widely used because nafamostat is not approved by regulatory agencies for this use.
- There is a desire to create a nafamostat for dialysis circuit anticoagulation outside Korea and Japan because RCA has a citrate toxicity risk and requires a complex, labor-intensive dosing protocol.
- The nafamostat asset was recently acquired by AcelRx from Lowell Therapeutics for the purpose of developing it for use in any extracorporeal circuit, including dialysis.
- In a study published in the journal Pediatric Nephrology comparing Nafamostat Mesilate with Citrate Anticoagulation in Pediatric Continuous Kidney Replacement Therapy, Dr. Stuart Goldstein, MD, FAAP, FASN, FNKF was the senior author.
- Goldstein holds the Clark D. West Endowed Chair at Cincinnati Children’s Hospital, where he is a Professor and Director of the Center for Acute Care Nephrology.
- Despite the fact that this study focuses on paediatric patients, the standard of care is the same for adults and children.
- Cost comparison between the two anticoagulation techniques was conducted as well as an analysis of the lifespan of the dialysis filter, blood loss, and bleeding incidence.
What did ACRX see in the review?
In the context of acute renal failure, AcelRx (ACRX) is excited at the prospect of developing nafamostat as a regional anticoagulant. Patients who underwent CRRT (also known as CKRT) with Nafamostat at a single Japanese hospital were compared to patients who underwent citrate at a single US hospital.